Alloreactive CD4+ and CD8+ T cell

Alloreactive CD4+ and CD8+ T cells are specialized subsets of T lymphocytes that recognize foreign major histocompatibility complex (MHC) molecules, a process central to the immunology of transplantation (PubMed: 28259710). CD4+ alloreactive T cells primarily recognize MHC class II molecules and produce cytokines like IL-2 and IFN-gamma to coordinate the immune response, while CD8+ alloreactive T cells recognize MHC class I and mediate direct cellular lysis via perforin and granzymes (StatPearls: NBK538235). These cells are the primary mediators of both acute and chronic graft rejection, as well as graft-versus-host disease (GVHD) following hematopoietic stem cell transplants (PubMed: 30103141). Therapeutic targeting of these cells involves various strategies, including global depletion using antithymocyte globulin or specific inhibition of signaling pathways using calcineurin inhibitors like tacrolimus and mTOR inhibitors like sirolimus (NIH: PMC4945363). While effective at preventing graft loss, the broad suppression of these T cell populations significantly increases the risk of opportunistic infections and reduces the body's ability to perform tumor immunosurveillance (PubMed: 25637363). Emerging therapies also explore the induction of regulatory T cells to counteract the activity of these alloreactive populations to promote long-term graft tolerance (PubMed: 29103141). Monitoring the activity and frequency of these cells is crucial for managing transplant patients and adjusting immunosuppressive regimens.

Other names

Donor-reactive T cellAllo-reactive T lymphocyteHost-reactive T cellAlloreactive T cell

The primary mechanisms of action for drugs targeting these cells include the inhibition of T-cell receptor signaling (Signal 1), the blockade of co-stimulatory pathways such as CD28-CD80/86 (Signal 2), the prevention of cytokine-mediated proliferation (Signal 3), and direct lymphodepletion (PubMed: 28259710, NIH: PMC4945363).